Robert C. Green is a medical geneticist, professor of medicine at Harvard Medical School, and associate member at the Broad Institute. He directs the Genomes2People Research Program and Preventive Genomics Service at Brigham and Women’s Hospital, researching medical, behavioral, and economic outcomes around genomic medicine implementation. Green led the first trials disclosing common complex disease risk (REVEAL Study) and the first prospective study of direct-to-consumer genetic testing customers (PGen Study). He currently leads or co-leads the first randomized trials to explore the implementation of medical sequencing in adults and newborns. Green was previously a faculty member at Boston University School of Medicine and at Emory University School of Medicine.
Previously
Genomic discoveries were supposed to transform medicine and move us to a new vision of preventive health care. But 15 years after the Human Genome Project was complete, that s...
The sequencing of the human genome – a complete map of the body’s three million base pairs – opened a window into disease processes, led to new diagnostic tools and personaliz...